The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
Add-on oral antihistamines or montelukast (Singulair) do not add much benefit. In three separate trials, researchers randomized 3398 adolescent and adult patients with moderate-to-severe SAR ...